Since the emergence of COVID-19, HDA members have used their extensive distribution networks, logistics expertise and experience in rising to the challenge of previous public health crises to respond to the pandemic. From managing unique inventory demands associated with the first hotspots, to ensuring providers have access to new treatments, to the preparation and ultimate distribution of vaccines once they are approved, distributors have closely collaborated with the federal and state governments each step of the way.
Since the enactment of the Drug Supply Chain Security Act in 2013, members of the pharmaceutical supply chain have undertaken efforts to meet each of the major milestones contained within the statute’s 10-year timeline to further secure the safety of the products being distributed. The industry’s progress to 2023 interoperability was top of mind as supply chain and other stakeholders came together at HDA’s recent Traceability Online Seminar.
On October 27, HDA and The Hill brought together policymakers, leaders in the pharmaceutical industry and public health experts to discuss the supply chain’s response during COVID-19. In conversation with Steve Clemons, Editor-in-Chief of The Hill, speakers provided key insights on ensuring the strength and resilience of the pharmaceutical supply chain during this unprecedented crisis. Below are five takeaways from the dialogue.